April 27, 2017
At the American Academy of Neurology annual meeting, researchers presented long-term efficacy and safety data supporting the recent FDA approval of Ingrezza for tardive dyskinesia in adults.
“We are very pleased to present additional robust data from the largest ever clinical program in tardive dyskinesia at this year’s American Academy of Neurology Annual Meeting,” Chris O'Brien, MD, FAAN, chief medical officer at Neurocrine, said in a press release. “Over 1,000 persons have participated in more than 20 Ingrezza clinical trials, with consistent and strong results demonstrated by the first and only FDA-approved treatment for adults with tardive dyskinesia. These expanded safety, efficacy and pharmacologic findings continue to illustrate Ingrezza’s differentiated potential and what it offers to an underserved community.”